Welcome to our dedicated page for Arena Pharmaceuticals news (Ticker: ARNA), a resource for investors and traders seeking the latest updates and insights on Arena Pharmaceuticals stock.
Arena Pharmaceuticals reports corporate developments tied to its biopharmaceutical operations, including operating and financial results, clinical and regulatory disclosures, material agreements, and capital-structure matters. Company announcements have also covered shareholder voting and governance topics, including inducement restricted stock unit grants made under Nasdaq Listing Rule 5635(c)(4) and its Amended and Restated 2021 Long-Term Incentive Plan.
Arena Pharmaceuticals (Nasdaq: ARNA) provided a corporate update and reported Q3 2021 financial results, highlighting significant advancements in clinical programs. The Phase 3 ELEVATE UC 12 trial reached full enrollment, with topline data expected in Q1 2022. The company also initiated a Phase 2 trial for temanogrel in Raynaud’s phenomenon. However, Q3 net loss increased to $196.3 million, primarily due to a $70 million expense for in-process R&D, leading to a net loss per share of $3.21. As of September 30, 2021, cash and equivalents stood at $800 million.
Arena Pharmaceuticals (NASDAQ: ARNA) announced the grant of inducement stock options and restricted stock units (RSUs) to new employees. The Compensation Committee approved these grants on October 5, 2021, with a grant date of October 15, 2021. Key grants include options for 36,000 shares and 7,000 RSUs to Chief Scientific Officer Lamine Mbow, and options for 14,500 shares and 24,500 RSUs to HR Senior VP Lucas Vitale. The inducement stock options have a seven-year term, with an exercise price of $62.89 per share, vesting over four years.
Arena Pharmaceuticals (NASDAQ: ARNA) announced it will release its third quarter 2021 financial results on November 4, 2021, after U.S. market close. The company will also host a Q&A session via conference call and live webcast at 4:30 PM ET the same day. The call will be accessible through their investor relations website. Arena Pharmaceuticals focuses on delivering crucial medicines to patients, showcasing its commitment to innovation in a rapidly changing market.
Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options and restricted stock units (RSUs) to 20 new employees. The stock options allow the purchase of 33,340 shares at an exercise price of $59.09, the stock's closing price on September 15, 2021. The options have a seven-year term and vest over four years. RSUs, totaling 15,655, will vest similarly over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support Arena's mission of delivering essential medicines to patients.
Arena Pharmaceuticals (Nasdaq: ARNA) announced two virtual R&D Investor calls focusing on its etrasimod programs. The first call, on September 21, 2021, at 10:30 a.m. ET, will cover gastroenterology, featuring speakers Robert Lisicki and William Sandborn. The second call is set for September 27, 2021, at 11:00 a.m. ET, focusing on dermatology with Doug Manion and Jonathan Silverberg. Additionally, Arena will participate in five investor conferences throughout September.
Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of stock options, performance restricted stock units (PRSUs), and restricted stock units (RSUs) to new employees as an inducement for their employment. The Compensation Committee approved these grants on August 10, 2021, with a grant date of August 15, 2021. Notably, the grants included stock options for 90,000 shares and RSUs for 15,000 shares to Doug Manion, Executive VP of Research and Development. The stock options have a seven-year term with an exercise price of $48.12, vesting over four years.
Arena Pharmaceuticals (Nasdaq: ARNA) reported its Q2 2021 financial results, highlighting a net loss of $146.1 million, up from $84.9 million in Q2 2020. Research and development expenses increased to $112.5 million, primarily due to advancing clinical studies. The company announced full enrollment in the Phase 3 ELEVATE UC 12 trial for etrasimod in ulcerative colitis, with data expected in Q1 2022. Additionally, a partnership with Aristea was formed to enhance the immunology pipeline. Cash reserves stood at $1 billion as of June 30, 2021.
Second Genome announced a strategic collaboration with Arena Pharmaceuticals (ARNA) on August 5, 2021, aimed at identifying microbiome biomarkers linked to clinical responses for etrasimod, a treatment for Crohn's disease. Utilizing its sg-4-sight platform, Second Genome will analyze data from Arena's CULTIVATE clinical trial. This partnership intends to improve patient stratification and treatment optimization. Second Genome is advancing its pipeline of precision therapies in inflammatory bowel disease and cancer, expecting clinical development to commence in 2022.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will announce its second quarter 2021 financial results on August 5, 2021, post U.S. market close. The company plans a live webcast at 4:30 PM ET to discuss these results with investors. Arena emphasizes its commitment to delivering crucial medicines while adapting to market changes. The press release includes forward-looking statements regarding corporate updates and potential risks, with a cautionary note about factors that may lead to differing actual results.
Arena Pharmaceuticals and Aristea Therapeutics have entered into a strategic collaboration focused on RIST4721, an oral CXCR2 antagonist for treating palmoplantar pustulosis (PPP). Arena will pay $60 million upfront and invest $10 million in Aristea's Series B financing. In return, Arena gains an exclusive option to acquire Aristea after completing a Phase 2b study of RIST4721. This partnership may also explore treatments for additional neutrophil-mediated diseases. Aristea recently secured $63 million in Series B financing.